Switch theme
Sign up to access all valuation multiples
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
1990
987
LTM Revenue $454M
LTM EBITDA $28.3M
$296M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Accuray has a last 12-month revenue (LTM) of $454M and a last 12-month EBITDA of $28.3M.
In the most recent fiscal year, Accuray achieved revenue of $447M and an EBITDA of $5.7M.
Accuray expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Accuray valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $454M | XXX | $447M | XXX | XXX | XXX |
| Gross Profit | $146M | XXX | $143M | XXX | XXX | XXX |
| Gross Margin | 32% | XXX | 32% | XXX | XXX | XXX |
| EBITDA | $28.3M | XXX | $5.7M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 1% | XXX | XXX | XXX |
| EBIT | $7.8M | XXX | $0.5M | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | 0% | XXX | XXX | XXX |
| Net Profit | -$1.9M | XXX | -$15.5M | XXX | XXX | XXX |
| Net Margin | 0% | XXX | -3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $104M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Accuray's stock price is $2.
Accuray has current market cap of $160M, and EV of $296M.
See Accuray trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $296M | $160M | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Accuray has market cap of $160M and EV of $296M.
Accuray's trades at 0.7x EV/Revenue multiple, and 17.1x EV/EBITDA.
Equity research analysts estimate Accuray's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Accuray has a P/E ratio of -83.4x.
See valuation multiples for Accuray and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $160M | XXX | $160M | XXX | XXX | XXX |
| EV (current) | $296M | XXX | $296M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 10.5x | XXX | 17.1x | XXX | XXX | XXX |
| EV/EBIT | 38.0x | XXX | 66.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -83.4x | XXX | -19.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -46.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAccuray's last 12 month revenue growth is 0%
Accuray's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Accuray's rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Accuray's rule of X is 7% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Accuray and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 104% | XXX | XXX | XXX |
| Rule of 40 | 2% | XXX | 4% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 7% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Accuray acquired XXX companies to date.
Last acquisition by Accuray was XXXXXXXX, XXXXX XXXXX XXXXXX . Accuray acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Accuray founded? | Accuray was founded in 1990. |
| Where is Accuray headquartered? | Accuray is headquartered in United States of America. |
| How many employees does Accuray have? | As of today, Accuray has 987 employees. |
| Who is the CEO of Accuray? | Accuray's CEO is Ms. Suzanne C. Winter. |
| Is Accuray publicy listed? | Yes, Accuray is a public company listed on NAS. |
| What is the stock symbol of Accuray? | Accuray trades under ARAY ticker. |
| When did Accuray go public? | Accuray went public in 2007. |
| Who are competitors of Accuray? | Similar companies to Accuray include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Accuray? | Accuray's current market cap is $160M |
| What is the current revenue of Accuray? | Accuray's last 12 months revenue is $454M. |
| What is the current revenue growth of Accuray? | Accuray revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Accuray? | Current revenue multiple of Accuray is 0.7x. |
| Is Accuray profitable? | Yes, Accuray is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Accuray? | Accuray's last 12 months EBITDA is $28.3M. |
| What is Accuray's EBITDA margin? | Accuray's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of Accuray? | Current EBITDA multiple of Accuray is 10.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
